The arrival of esketamine nasal spray represents a groundbreaking change in the management of complex depression across the EU . While previously requiring specialist administration, this option allows for a more level of patient autonomy , although rigorous monitoring remains crucial . Initial data suggest benefit for individuals who have shown in